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Twenty macaques were used to evaluate the ability of nonpathogenic SIVmac or nonpathogenic chimeric SIV-HIV (SHIV)
to induce protection in macaques against superinfection with a pathogenic variant of SHIV (SHIVKU-1) originally containing
the tat, rev, vpu, and env of HIV-1 (strain HXB2) in a genetic background of SIVmac239. Specifically, three macaques inoculated
with molecularly cloned, macrophage-tropic SIVmacLG1 developed an early systemic infection but recovered with only traces
of SIVmac DNA in visceral lymphoid tissues. These animals were then inoculated parenterally with pathogenic SHIVKU-1 . All
three animals resisted infection with SHIVKU-1 , as indicated by lack of virus recovery and absence of SHIV-specific env and
vpu sequences in the visceral lymphoid tissues and multiple regions in the CNS. We also examined the ability of five
macaques that had been inoculated with nonpathogenic SHIV (NP-SHIV) to withstand challenge with the pathogenic
SHIVKU-1 . Like the SIVmacLG1-inoculated macaques, these animals also resisted SHIVKU-1 challenge as judged by the inability
to recover infectious virus, normal CD4/ T cell counts, and the absence of SHIVKU-1 signature sequences in the lymph node
tissue. Thus, eight of eight animals that developed control over primary lentivirus infections had also developed resistance
to infection with pathogenic SHIVKU-1 . Three groups of macaques were used as controls for this study. The first group
consisted of six macaques inoculated with SHIVKU-1 alone. All animals developed viremia, showed severe loss of CD4/ T
cells within 4 weeks, and succumbed to AIDS within 6 months. The second group of three macaques was inoculated first
with SHIVKU-1 and inoculated later with uncloned, neurovirulent SIVmac7F-Lu. A third group of three macaques was inoculated
with SIVmac7F-Lu followed by inoculation with SHIVKU-1 . PCR analyses using oligonucleotide primers specific for the SIV or
HIV env revealed that macaques from the last two groups had widespread infection with both SHIVKU-1 and SIVmac , indicating
that animals that failed to control productive replication of either SHIVKU-1 or SIVmac7F-Lu could not resist superinfection
with the other virus. These data indicate that sterilizing immunity against the virulent SHIV could be induced in animals that
had experienced an immunizing infection. Moreover, the divergence of the envelope glycoprotein of the protective avirulent
and virulent challenge virus suggests that a single vaccine could protect against infection with a virus containing a different
envelope glycoprotein. q 1997 Academic Press
INTRODUCTION virus (Haynes et al., 1996). Classically, cell-mediated im-
mune responses and virus-neutralizing antibodies are
The pathogenesis of human immunodeficiency virus considered important in controlling and/or preventing
type 1 (HIV-1) infection in humans revolves around an other viral infections and there is a suggestion that devel-
acute phase of productive virus replication, followed by a opment of cytotoxic T-cell responses to HIV proteins cor-
control phase during which anti-HIV cellular and humoral relates with control of virus replication during the acute
immune responses to the virus become mobilized and a phase of HIV-1 infection (Koup et al., 1994). On the other
later phase in which virus replication undergoes resur- hand, given the wide heterogeneity of the viral envelope
gence, leading to the well-known loss of CD4/ T lympho- glycoprotein, the question arises as to whether effective
cytes, loss of immune competence, and onset of opportu- broad-spectrum humoral immune responses could ever
nistic infections (Schnittman and Fauci, 1994). The mech- be induced against the virus swarm with vaccines
anisms which mediate the development of the last phase (Fenyo, 1994; Burns and Desrosiers, 1994).
remain unknown but the antiviral immune responses that Another unknown parameter in HIV pathogenesis is
develop earlier suggest that virus replication can be con- whether virus strains causing infection in nature vary in
trolled (Koup et al., 1994). However, the precise immuno- virulence. Theoretically, this could be one explanation
logical mechanisms essential for controlling HIV replica- for the wide disparity in incubation periods of HIV dis-
tion are unknown and therefore it is not possible as yet ease whose onset may extend from months to several
to specify correlates of protective immunity against this years after infection. Since virulent viruses in general
replicate faster and to higher titers than avirulent viruses
and given that prolonged HIV viremia (high rate of virus1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (913) 588-5599. E-mail: estephen@kumc.edu. replication) has a poor prognosis whereas early control
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over virus replication with sustained inhibition of replica- MATERIALS AND METHODS
tion predicts long survival (Mellors et al., 1996), it is possi-
Cell cultures and virus stocksble that infection with an avirulent virus could confer
immunity against superinfection with a more virulent Cells from the C8166 cell line were used as indicator
strain. This concept in vaccine development against HIV- cells to measure infectivity and cytopathicity of the vi-
1 meets with two theoretical objections: first, infection ruses used in this study. C8166 cells were maintained
with HIV-1, or even an avirulent virus, probably results in RPMI 1640, supplemented with 10 mM HEPES buffer,
in indefinite viral persistence as measured by survival of pH 7.3, 5 1 1005 2-mercaptoethanol, 2 mM glutamine,
the lentiviral genome in host DNA, and second, mutation 50 mg/ml gentamicin, and 10% fetal bovine serum (FBS).
and recombination of the virus can result in reversion of The viruses used in this study were as follows:
an avirulent genotype to a virulent genotype. (1) SIVmac7F-Lu: This virus was isolated from the lung
Studies on simian immunodeficiency virus (SIVmac), a of macaque 7F that was inoculated with SIVmac239 and
virus that causes a spectrum of disease syndromes in developed severe interstitial pneumonia and AIDS at 1
macaques that is similar to that produced by HIV-1 in year postinoculation. A 10% (w/v) cell-free homogenate
humans, have thrown some light on protective mecha- of the pneumonic lung was used as the virus stock. The
pathogenic properties of this virus have been previouslynisms induced by primate lentiviruses (Letvin and King,
described (Zhu et al., 1995).1990; Desrosiers, 1995). First, strains of SIVmac do in fact
(2) SIVmacLG1: This is a chimeric virus whose env genevary immensely in virulence. Whereas uncloned viruses
was amplified from the pneumonic lung of macaque 7Fsuch as B670 (Murphey-Corb et al., 1989; Sharer et al.,
and was used to replace the corresponding region in the1988; Murray et al., 1992), SIVmac251 (Daniel et al., 1985)
SIVmac239 genome. The construction and macrophage-and molecularly cloned SIVmac239 (Kestler et al., 1990)
tropic properties of this virus have been previously char-are extremely virulent, some molecularly cloned, macro-
acterized (Stephens et al., 1995a).phage-tropic strains of SIVmac not only are highly attenu-
(3) SHIV-4: The DNA of this virus was provided by Dr.ated in virulence (Banapour et al., 1991; Marthas et al.,
Sodroski at Harvard University and contains the tat, rev,1993; Joag et al., 1995), but induce protection against the
vpu, and env genes of HXB2 in a background of SIVmac239virulent SIVmac (Clements et al., 1995). Second, deletion
(Li et al., 1992). This virus is avirulent in macaques andof specific regulatory genes, such as nef, from the ge-
was passaged sequentially in both rhesus and pig-tailednome of SIVmac239 converted this virus to an avirulent
macaques. Passage 1, 2, and 3 viruses from rhesus ma-phenotype that caused immunizing infections in adult
caques and passage 2 virus from pigtailed macaquesmacaques which protected against virulent SIVmac239
were avirulent. The original virus and the passaged mate-(Kestler et al., 1991). However, the SIVmac infection in
rial that failed to cause disease have been groupedmacaques is only an analog model of the human infec-
together under Results as nonpathogenic SHIV ortion and there are no strains of SIVmac that are antigeni-
NP-SHIV.cally similar to subtypes of HIV-1 (Desrosiers, 1995).
(4) SHIVKU-1: This virus is a pathogenic variant of SHIV-Therefore efficacy of broad-spectrum protection against
4 derived by sequential passage in pig-tailed macaquesdifferent types of virus cannot be determined with this
as previously described (Joag et al., 1996, 1997a, 1997b).model.
Following inoculation into macaques, this virus causedOur recent development of a pathogenic SHIV which
almost complete depletion of CD4/ T cells within 4carries the envelope glycoprotein of HIV-1 and which
weeks (Joag et al., 1996, 1997a, 1997b). The amino acidcauses severe loss of CD4/ T cells and AIDS in ma-
substitutions that developed in the envelope glycoproteincaques within six months, irrespective of the route on
of the SHIVKU-1 stock have recently been reported (Ste-inoculation (Joag et al., 1996, 1997a, 1997b), has allowed
phens et al., 1997).
us to inquire directly whether prior infection in macaques
with virulent or avirulent virus would affect replication
Virus inoculation and SHIV challengeand pathogenesis of viruses inoculated later. Further, our
model system allowed us to ask whether the infection Five groups of monkeys were used in this study. (1)
with virus containing the envelope glycoprotein of SIVmac Six pig-tailed macaques (18A, 18B, 18D, 18E, 24B, and
can modulate the infection and replication of SHIV, car- 24C) were inoculated with pathogenic SHIVKU-1 either by
rying the envelope glycoprotein of HIV-1. Studies on 14 the intravaginal route (macaques 18A, 18B, 18D, and 18E)
doubly inoculated animals showed that the ability of the or by the intravenous route (24B and 24C). All of these
second virus to replicate and cause disease was predict- macaques developed severe CD4/ loss and were main-
able on the basis of the outcome of the prior infections. tained until they developed AIDS. The results of the infec-
Irrespective of the viral envelope glycoprotein in the ‘‘im- tions have been previously published (Joag et al., 1997b)
munizing virus,’’ animals that controlled replication of the and some of the data are reproduced here as a point of
first virus were resistant to superinfection with patho- reference for the other studies repeated below. (2) Three
pig-tailed macaques were inoculated intravaginally (18Cgenic SHIVKU-1 .
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or 18F) or intravenously (24D) with SHIVKU-1 . At 4 weeks were then observed for development of syncytial cyto-
pathic effects (CPE) during a 7-day period. The results(macaque 24D) and 10 weeks (macaques 18C and 18F),
these animals were inoculated intratracheally with 104 were expressed as the number of cells producing infec-
tious virus per 105 cells (ICA) (Joag et al., 1994 a,b).TCID50 of SIVmac7F-Lu. Animals were inoculated with
SIVmac7F-Lu via the intratracheal route because in a pre-
vious study (Zhu et al., 1995) we showed that macaques PCR analysis for the presence of viral sequences in
inoculated with this virus via this route developed intersti- neural and nonneural tissues
tial pneumonia and neurological disease. (3) Three pig-
tailed macaques (28X, 28Y, and 28Z) were inoculated Tissues from inoculated animals were first screened
for the presence of SIV and/or SHIV sequences usingintratracheally with 104 TCID50 of SIVmac7F-Lu and 4
weeks later were inoculated intravenously with 104 the oligonucleotide primers specific for both SIV and
SHIV and the PCR technique. Total cellular genomic DNATCID50 of SHIVKU-1 . (4) Three pigtailed macaques (P7A,
PIt, and PMq) were inoculated intratracheally with was extracted from six visceral organs (liver, spleen,
lymph node, lung, small intestine, and kidney) and 12SIVmacLG1 and 86 weeks later were inoculated intrave-
nously with SHIVKU-1 . (5) Three rhesus macaques (8A, 8B, regions of the central nervous system (frontal, parietal,
occipital, and temporal cortices, the internal capsule,and 8D) and two pig-tailed macaques (PLc and PRc)
were used in the derivation of a pathogenic SHIV. The basal ganglia, midbrain, brain stem, cerebellum, and the
cervical, thoracic, and lumbar regions of the spinal cord).details of the passage of nonpathogenic SHIV in these
macaques have been previously described (Joag et al., The DNA was used as a template in nested polymerase
chain reactions (PCRs) (Saiki et al., 1985, 1988) to amplify1996; Stephens et al., 1996). None of these macaques
developed significant CD4/ T-cell loss or a sustained SIV gag sequences which were common to both viruses.
The gag-specific oligonucleotides and the conditions forperiod of virus replication. The viruses in these inocula
therefore were designated NP-SHIV. The five animals amplification were exactly as described previously (Joag
et al., 1994b).were inoculated intravenously with 104 TCID50 of
SHIVKU-1 between 70 and 80 weeks after receiving Once tissues containing SIV and/or SHIV sequences
were identified, oligonucleotide primers specific for theNP-SHIV.
env genes of SIV and SHIV were used in PCR to distin-
Processing of blood and tissue samples guish between these viruses. For amplification of SIV-
specific sequences, the oligonucleotide primers used in
Heparinized blood was centrifuged to separate the
the first round were 5*-GGCTAAGGCTAATACATCTTC-
plasma from the buffy coat. Plasma was assayed directly
TGCATC-3* and 5*-ACCCAAGAACCCTAGCACAAAGAC-
for infectivity in C8166 cells and the cells were centri-
CCC-3*, which are complementary to bases 6565 to 6591
fuged through Ficoll-Hypaque density gradients to isolate
and 8179 to 8205 of SIVmac239, respectively (Regier andperipheral blood mononuclear cells (PBMC). Portions of
Desrosiers, 1990). One microgram of genomic DNA was
tissue specimens obtained at necropsy were processed
used in the PCR containing 4.0 mM MgCl2 , 200 mM eachas follows: (1) frozen at 0807 and used as the source of
of the four deoxynucleotide triphosphates, 100 pM each
genomic DNA; (2) used to prepare cell-free, 10% homoge-
oligonucleotide primer, and 2.5 U of Taq polymerase
nates (w/v) which were assayed for infectivity in C8166
(Perkin–Elmer Cetus, Norwalk, CT). The template was
cells; (3) used to prepare single-cell suspensions by
denatured at 957 for 3 min and PCR amplification per-
passing through a fine mesh (spleen and lymph node)
formed with an automated DNA Thermal Cycler (Perkin –
and to assess the number of cells producing infectious
Elmer Cetus) for 35 cycles using the following profile:
virus by co-cultivation with C8166 cells; (4) used in ali-
denaturation at 927 for 1 min, annealing at 557 for 1 min,
quots of cells cultivated in macrophage differentiation
and primer extension at 727 for 3 min. Amplification was
medium (MDM) and in sRPMI containing phytohemag-
completed by incubation of the PCR for 10 min at 727.
glutinin/IL-2 to test for infectious virus produced in mac-
One microliter of the PCR product described above was
rophages and lymphocytes, respectively; (5) used to pre-
used in a nested PCR using the same reaction conditions
pare tissue explants in MDM to test for productive virus
described above. For the second round of amplification,
replication in tissue macrophages; and (6) fixed in 10%
the nested set of primers were 5*-GTAAGTATGGGATGT-
buffered formalin, embedded in paraffin, sectioned, and
CTTGGGAATCAG-3* and 5*-GACCCCTCTTTTATTTCT-
stained with hematoxylin and eosin for histopathological
TGAGGTGCC-3*, which are complementary to bases
examination. All of these procedures have been de-
6598 to 6624 and 8158 to 8184 of the SIVmac239 genome,scribed previously (Joag et al., 1994 a,b).
respectively. For detection of SHIV-specific envelope se-
quences, the oligonucleotides used in the first-roundAssessment of virus burden and CD8 depletion
PCR were 5*-GACTAATAGAAAGAGCAGAAGACAGTG-experiements
GCA-3* and 5*-AGTGCTTCCTGCTGCTCCCAAGAACCC-
3* (antisense), which are complementary to nucleotidesSerial twofold dilutions of PBMC, lymph node, lung, or
spleen cells were inoculated into C8166 cells, which 6194 to 6223 and 7784 to 7810 of the HXB2 genome,
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respectively (Wong-Staal et al., 1985). For nested PCR of this tissue and hence, if productive replication of the chal-
lenge virus occurred, it would have been detected in thethe SHIV sequences, the oligonucleotides used were 5*-
ATGAGAGTGAAGGAGAAATATCAGCAC-3* and 5*-GAA- lymph node tissue. For the first round, amplification was
done with the oligonucleotides 5*-CCGGCTGGTTTTGCG-CAAAGCTCCTATTCCCACTGCTCT-3* (antisense), which
were complementary to nucleotides 6224 to 6250 and ATTCTAAAA-3* (sense) and 5*-TTACAGTAGAAAAATTCC-
CCTCCA-3* (antisense), which are complementary to nucle-7754 to 7780 of the HXB2 genome, respectively. To con-
firm the specificity of the PCR products, the DNA in the otides 6880 to 6903 and 7357 to 7380 of the HIV-1 (HXB2)
genome, respectively (Wong-Staal et al., 1985). Second-gel was transferred onto nitrocellulose by the Southern
technique and then hybridized with a 32P-labeled gp120 round amplification was done with oligonucleotide primers
5*-ACAAATGTCAGCACAGTACAATGT-3* (sense) and 5*-probe (either SIVmac239 or HXB2) generated by the ran-
dom primer labeling method (Feinberg and Vogelstein, CCTGAGGATTGCTTAAAGATTATT-3* (antisense), which
are complementary to nucleotides 6940 to 6963 and 72971983). The blot was washed for 30 min at 657 with 21
SSC/0.5% SDS, 0.21 SSC/0.5% SDS and finally with 0.11 to 7320 of the HIV-1 (HXB2) genome, respectively (Wong-
Staal et al., 1985). The conditions for amplification wereSSC/0.5% SDS. The blot was then exposed to X-Omat
film and processed using standard autoradiographic pro- identical to those described above. The amplified products
(390 bp) were separated by electrophoresis in a 1% agarosecedures. The presence of HIV-1 sequences in tissues
was confirmed by PCR amplification of a 450-basepair gel, isolated, and molecularly cloned into the pGEM-T vec-
tor according to the manufacturer’s instructions. Plasmidsfragment corresponding to vpu, a gene not found in the
SIV genome. For the first round of PCR amplification of containing gp120 sequences were sequenced by primer-
directed dideoxy sequencing using Sequenase enzymethe vpu gene, oligonucleotide primers 5*-CCTAGACTA-
GAGCCCTGGAAGCATCC-3* and 5*-GTACCTCTGTAT- (U.S. Biochemicals, Cleveland, OH) and 35S-dATP. The
PCGENE Sequence Analysis package was used to com-CATATGCTTTAGCAT-3* (antisense) were used, which
are complementary to nucleotides 5845 to 5870 and 6393 pare the derived lymph node sequences to those of HIV-
1(HXB2) and SHIVKU-1 .to 6419 of the HIV-1 (HXB2) genome, respectively (Wong-
Staal et al., 1985). For the second round of amplification,
oligonucleotide primers 5*-TTAGGCATCTCCTATGGC- RESULTS
AGGAAGAAG-3* (sense) and 5*-CACAAAATAGAGTGG-
Macaques infected with SHIVKU-1 failed to controlTGGTTGCTTCCT-3* were used, which are complemen-
replication of the virus and were easily
tary to nucleotides 5956 to 5982 and 6386 to 6412 of the
superinfected with SIVmacHIV-1 (HXB2) genome, respectively (Wong-Staal et al.,
1985). The conditions for amplification were identical to In a previous report (Joag et al., 1997b), we showed
that six macaques inoculated with SHIVKU-1 developedthose described above. In all cases, the presence of HIV-
1 env sequences was confirmed by the presence of vpu fulminant infections characterized at the cellular level
by productive infection in CD4/ T cells and in cells ofsequences.
macrophage lineage, and at the animal level by precipi-
tous loss of the CD4/ T and viremia. The animals devel-Differentiation between nonpathogenic SHIV
oped fatal AIDS although none developed lentiviral (LV)and pathogenic SHIV
interstitial pneumonia or LV encephalitis. Values of CD4/
T-cell counts and viremia for these six animals are repro-For macaques 8A, 8B, 8D, PLc, and PRc, the NP-SHIV
used to inoculate the macaques and the pathogenic duced from the previous report to provide a reference
point for three other previously unreported animals inoc-SHIVKU-1 challenge virus were distinguished by sequence
analysis of the V3 domain of the envelope glycoprotein ulated with SHIVKU-1 that were reinoculated with SIVmac
7F-Lu. As shown, all nine animals became highly viremicgene. We recently characterized the amino acid substitu-
tions that occurred in the env of the SHIVKU-1 challenge during the first 2 weeks following inoculation with
SHIVKU-1 (Table 1A). This was followed by severe loss ofvirus stock and found that they included four consensus
amino acid substitutions within the V3 domain of the gp120 the CD4/ T-cell subset of mononuclear cells from blood
(Table 1B) and lymphoid tissues (data not shown). Vire-region of the envelope glycoprotein (asparagine to serine,
arginine to isoleucine, isoleucine to methionine, and aspar- mia decreased initially, coincident with loss of the CD4/
T-cell population, and fluctuated later, coincident withagine to aspartic acid at positions 300, 304, 320, and 325,
respectively) (Stephens et al., 1997). We used these amino input of virus into blood from infected macrophage popu-
lations. However, regardless of viral p27 levels in blood,acid substitutions in the pathogenic SHIVKU-1 stock as a
marker to distinguish between the NP-SHIV inoculum and virus was obtainable from the animals throughout their
infections by co-cultivation of their PBMC with indicatorthe challenge virus. Nested PCR with oligonucleotides that
amplified the V3 domain of the gp120 was performed with cells, without need for depletion of CD8/ T cells. By these
criteria, we concluded that none of the nine macaqueslymph node DNA from each of the five macaques as a
template. We chose to analyze the lymph node tissue be- had developed control over virus replication. Three of
these animals 18C, 18F, and 24D were selected for rein-cause the SHIV virus burdens were consistently high in
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TABLE 1A
SIV p27 Concentration (pg/ml) in Plasma from Infected Macaques
SHIVKU-1 only SHIVKU-1 then SIVmac 7F-Lu
Week 18A 18B 18D 18E 24B 24C 18C 18F 24D
1 0 0 758 313 4187 3357 0 0 3229
2 4178 7275 498 285 82 44 4931 0 914
3
4 72 0 0 0 161 10 0 568 0
5
6 162 0 0 0 247 6 0 0 0
7 0 0
8 329 0 0 0 14 0 0 0 484
10 2717 0 0 0 15 0 0 0 185
12 0 58 0 0 11 0 0 70
13 0 0 0
14 0 0 269
15 0 0 93
16 0 0 0
17 148 220 0 0 259 610
18 0 0
19 208 558 165 3068 1123
20 341
21 0 1052
22
23 51 3869
24
25
26 0
Note. Double underline indicates the time of superinfection.
oculation with SIVmac7F-Lu. Viremia persisted in all three virus recovery from PBMC of macaque PMq, between
animals and all three became severely ill. Macaques 18C Weeks 4 and 8, PBMC of all three animals failed to pro-
and 18F died at Weeks 18 and 22, respectively, and the duce virus beyond 8 weeks postinoculation, even after
third, 24D, was killed at Week 28. We used nested PCR depletion of CD8/ T cells (CD8/ depletion performed at
and oligonucleotides that specifically amplified the env Weeks 14, 19, 23, 39, 44, and 69). None of the animals lost
gene of SIVmac to determine whether the animals had CD4/ T cells and all three developed prominent antibody
become infected with the latter virus. Figure 1 shows responses to SIVmac as shown by immunoprecipitation
that sequences specific for SHIVKU-1 and SIVmac7F-Lu results (data not shown). As expected, none of the sera
were easily detected in macaque 18F. Table 2 summa- recognized the envelope glycoprotein (gp120) of HIV-1.
rizes the PCR results and showed that all three animals PCR analysis was performed on blood and lymphoid tis-
did become infected with SIVmac7F-Lu. They developed sues from these animals to determine whether they had
AIDS typically caused by SHIVKU-1 , but in addition they remained infected with SIVmacLG1 despite development
developed interstitial pneumonia and encephalitis typi- of immune responses. All three animals had viral DNA
cally caused by SIVmac7F-Lu. in lymph nodes, spleen, and GI tract and two had viral
DNA in selected regions of the brain. By these criteria,
Immunizing infections with SIVmac precluded these animals had developed control over replication of
superinfection with pathogenic SHIVKU-1 this lentivirus although they remained infected. They
were monitored for 86 weeks to ensure lack of viral resur-We sought to determine next whether macaques that
gence. At this time, we inoculated them intravenouslyhad been infected with a relatively avirulent virus such
with undiluted SHIVKU-1 and examined their tissues 4 toas macrophage-tropic SIVmacLG-1 would resist or suc-
8 weeks later for evidence of infection with SHIVKU-1 . Thiscumb to infection after challenge with SHIVKU-1 . Ma-
virus was not recovered from PBMC of any of the threecaques 7A, PIt, and PMq were inoculated intratracheally
animals when examined between Week 1 and the timewith SIVmacLG1 and then observed for pathogenesis. As
of euthanasia. They did not become viremic and did notshown in Table 3, all three animals became infected with
lose CD4/ T cells. Further, no HIV env sequences werethis virus as determined by identification of circulating
detectable in samples of 106 PBMC. The animals wereinfected mononuclear cells in blood during the first 4
weeks after inoculation. However, except for occasional euthanized between Weeks 6 and 7 after challenge with
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TABLE 1B
CD4/ Counts in PBMC from Infected Macaques
SHIVKU-1 only SHIVKU-1 then SIVmac 7F-Lu
Week 18A 18B 18D 18E 24B 24C 18C 18F 24D
02 632 1825 566 596 789 1588 1286
01 1005 1269
0 1055 645 1430 962 2909 1199 1223 1613
1 1583 1729 621 499 329 130 1574 2446 1180
2 694 114 5 30 34 70 488 1293 5
3
4 9 4 6 20 26 28 10 137 2
5
6 3 2 11 6 9 11 11 47 2
7 10 14
8 2 5 2 6 16 12 14 75 5
10 1 22 3 25 3 3 10 96 8
12 5 6 29 5 143 8 86 529
13 2 5 61
14 2 242 466
15 4 9 36
16 4 5 5
17 4 23 14 1 2 25
18 4 4
19 1 2 3 2 3
20 8
21 1 2 6
22 8
23 8 1
24
25
26
Note. Double underline indicates the time of superinfection.
SHIVKU-1 , and tissues were examined for viral DNA. PCR similar to that caused by SHIVKU-1 . Three animals, 28X,
showed that no HIV env or vpu sequences were present 28Y, and 28Z, were inoculated intratracheally with 1 ml
in spleen, mesenteric lymph nodes, lung, kidney, liver, of SIVmac 7F-Lu and their peripheral blood was examined
or 12 regions of the brain from any of the three animals later for evidence of infection. As shown in Table 5, all
(Fig. 1; Table 4). Thus, the three macaques which had three animals became viremic by the first week following
developed an immunizing infection with SIVmacLG-1 had inoculation and remained in this condition for the next 4
become resistant to infection with pathogenic SHIVKU- weeks. During this period, virus was easily recovered
1 . The significance of these data is that the envelope from peripheral blood in both plasma and mitogen-
glycoproteins of the immunizing and challenge viruses treated PBMC cultures. Interestingly, despite the highly
are distantly related yet protection against superinfection productive infection with this virus, none of the animals
was induced by the first virus against the second. lost CD4/ T cells (Table 5). Nevertheless, the three had
clearly failed to control replication of SIVmac7F-Lu.
Macaques that failed to control infection with The animals were inoculated with SHIVKU-1 during the
SIVmac7F-Lu were susceptible to infection with fourth week of infection with SIVmac7F-Lu. As shown in
pathogenic SHIVKU-1 Table 5, two of the three animals lost CD4/ T cells precip-
itously within the subsequent 2 weeks. This loss becameIn order to explore SIVmac/SHIV superinfection phe-
very prominent in all three animals by Week 10, followingnomena further, we inquired whether SIVmac7F-Lu-in-
the kinetics of CD4/ T cell loss typically seen in animalsfected macaques that failed to control replication of this
infected with SHIVKU-1 . Viremia persisted in all three ani-virus were susceptible or resistant to superinfection with
mals and all three became severely ill. Macaques 28YSHIVKU-1 . This is the reciprocal of Experiment 2 in which
and 28Z died during Week 18 and the third, 28X, wasthree SHIVKU-1-infected animals were challenged with
killed at Week 28. Examination of PBMC and lymph node,pathogenic SIVmac 7F-Lu. Whereas SIVmacLG-1 had
spleen, lungs, and brain showed infection with bothcaused an immunizing type of infection in macaques,
SIVmac7F-Lu caused an uncontrolled productive infection SIVmac and SHIVKU-1 . All three animals had CD4
/ T-cell
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FIG. 1. Analysis of tissue DNAs isolated from macaques 18F and PIt at necropsy for the presence of SHIV- and SIV-specific sequences. DNA
was extracted and used in nested PCR using the appropriate oligonucleotide primers specific for SHIV and SIV as described in the text. Ten
microliters of the reaction products were run in 1% agarose gels and stained with ethidium bromide. Note that with macaque 18F, which did not
control his SHIV infection, both SIV and SHIV were easily detected whereas with macaque PIt, which controlled his infection with SIVmacLG1, SIV
but not SHIV sequences were detected. (A) 1% agarose gel showing the presence of SIV sequences in DNA samples from 18 tissues from macaque
18F. (B) 1% agarose gel showing the presence or absence of SHIV sequences in DNA samples from 18 tissues from macaque 18F. (C) 1% agarose
gel showing the presence or absence of SIV sequences in DNA samples from 18 tissues from macaque PIt. (D) 1% agarose gel showing the
absence of SHIV sequences in DNA samples from 18 tissues from macaque PIt. Order of gels: Lane 1, mesenteric lymph node; Lane 2, spleen;
Lane 3, lung; Lane 4, liver; Lane 5, kidney; Lane 6, small intestine; Lane 7, frontal cortex; Lane 8, parietal cortex; Lane 9, occipital cortex; Lane 10,
temporal cortex; Lane 11, internal capsule; Lane 12, basal ganglia; Lane 13, midbrain; Lane 14, brain stem; Lane 15, cerebellum; Lane 16, cervical
spinal cord; Lane 17, thoracic spinal cord; Lane 18, lumbar spinal cord; Lane 19, positive control; Lane 20, negative control. The positive control
used was DNA from the lymph node tissue from macaque PPc whose gp120 region was previously amplified, cloned, and sequenced (Stephens
et al., 1996). The negative control was DNA isolated from PBMC of uninfected macaques.
loss, consistent with infection with SHIVKU-1 , and pneu- taining infectious virus from 8B). All five animals had
monia and encephalitis, consistent with infection with become infected as determined by virus recovery from
SIVmac7F-Lu. PCR confirmed the double infection in sev- PBMC during the first 2 weeks following inoculation, as
eral tissues (Table 6). Thus, similar to the animals inocu- previously reported (Joag et al., 1996; Stephens et al.,
lated first with SHIVKU-1 and subsequently with SIVmac7F- 1996). Thereafter, except on rare occasions, virus could
Lu, the three animals inoculated with the same viruses not be recovered from PBMC, even after prior depletion
in reciprocal order had the same fate. All of our data of CD8/ T cells. Nonetheless, the viral genome was pres-
thus showed that if the animals developed a productive ent in DNA extracted from PBMC and from lymph nodes
infection with the first virus, they failed to develop any which were biopsied between Week 60 and Week 80
kind of resistance that could protect against challenge following inoculation (data not shown). Thus, all five ani-
with a second, distantly related virus. mals had become persistently infected at a low level with
SHIV even though they controlled productive replication
Immunizing infection with NP-SHIV precluded of the virus (note similarity to animals infected with
superinfection with pathogenic SHIVKU-1 SIVmacLG1). None developed loss of CD4
/ T cells and
all five had produced both binding antibodies to SHIVThe foregoing studies had shown that all macaques
proteins and neutralizing antibodies to the virus. As ex-that succumbed to productive infection after inoculation
pected, none of the five immune sera recognized gp120with pathogenic virus were fully susceptible to superin-
of SIVmac in immunoprecipitation tests (data not shown).fection and development of pathogenic expression of the
The five animals that were originally inoculated withsecond virus. In contrast, the three animals inoculated
NP-SHIV and challenged with SHIVKU-1 were expected towith attenuated SIVmacLG1, whose replication was
succumb to infection, if not disease, caused by the latterbrought under control rapidly, were resistant to superin-
virus. However, no virus was recovered from PBMC fromfection. We explored this concept further in animals
any of the five animals that were examined weekly forinfected with NP-SHIV and challenged them with
the 4 weeks and biweekly thereafter. The animals didSHIVKU-1 . During serial passage of SHIV in macaques
not become viremic and none lost CD4/ T cells. Thein our attempt to select for pathogenic SHIV, we had
five animals were euthanized between 4 and 32 weeksinoculated eight animals with material containing infec-
after challenge, and visceral lymphoid tissues and CNStious virus. Macaque 8A was inoculated with the cloned
were examined for evidence of infection with SHIVKU-1 .SHIV-4; macaques 8B, PLc, and PRc were inoculated
Because the oligonucleotides used in the nested PCRwith passage 2 material (bone marrow cells containing
could not distinguish between the NP-SHIV used to inoc-infectious virus from macaque 8A) and macaque 8D was
inoculated with passage 3 virus (bone marrow cells con- ulate the macaques and the SHIVKU-1 , we determined the
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TABLE 2 the results from both virological and molecular virological
studies indicated that all five macaques inoculatedPresence of SIVmac or SHIV Sequences in Macaque Tissues
with NP-SHIV resisted superinfection with pathogenicInoculated with SHIVKU-1 Followed by Superinfection with SIVmac
7F-Lua SHIVKU-1 .
SIVmac SHIV DISCUSSION
Macaque Macaque The main purpose for development of a virulent SHIV
was to use it as a model of HIV-1 (with which SHIVTissue 18C 18F 24D 18C 18F 24D
shares a common envelope glycoprotein) to determine
PBMC / / / / / / whether vaccines would protect macaques against dis-
Mesenteric LN / / / / / / ease, if not infection caused by the virulent virus. In this
Spleen / / / / / / preliminary study, using three macaques infected with
Lung / / / / 0 /
avirulent SIVmacLG-1 and five macaques infected withLiver 0 / / / 0 0
avirulent NP-SHIV for challenge with virulent SHIVKU-1 ,Kidney / / 0 / / /
Small intestine / / / / 0 / we showed that whereas nine macaques inoculated with
Frontal cortex / / 0 / 0 / SHIVKU-1 (six reported previously by Joag et al., 1997b,
Parietal cortex 0 / 0 / 0 / and three others in this study) developed viremia and
Occipital cortex 0 / 0 / 0 /
rapid loss of CD4/ T cells, none of the eight animalsTemporal cortex / / 0 / 0 /
previously infected with nonpathogenic viruses becameInternal capsule / / 0 / 0 /
Basal ganglia 0 / 0 / / / infected with the SHIVKU-1 . Although not designed as vac-
Midbrain / / 0 / 0 / cines, the two avirulent viruses caused a similar type of
Brain stem / / 0 / 0 / infection that would be expected of a live virus vaccine.
Cerebellum 0 / / / / 0
Both agents underwent transient productive replicationCervical SC / / / / 0 0
that was brought under control by mobilized defenseThoracic SC 0 / / / 0 /
Lumbar SC 0 / 0 / / / mechanisms even though these failed to eliminate virus-
infected cells from tissues as determined by the pres-
a The presence of SIVmac or SHIV sequences was determined using ence of viral DNA by PCR. As a prelude to designed
oligonucleotides and nested PCR specific for each env gene.
vaccine studies that are currently under way, we used
sequence of the V3 domain of the env recovered from
TABLE 3
the lymph nodes of these macaques. We have shown
Infectious Cells and CD4/ Counts in PBMC from Macaquesthat the SHIVKU-1 stock has four consensus amino acid
Inoculated with SIVmac LG1 and then SHIVKU-1changes within the V3 region (Stephens et al., 1997). The
gp120 region of env was amplified, molecularly cloned, Infectious cells/106 CD4//ml
and sequenced as described above. As shown in Fig. 2,
Week P7A PIt PMq P7A PIt PMqthe V3 regions sequenced from macaque 8A had either
no substitutions or an arginine-to-isoleucine substitution
01 2141 1205 1863at position 304 of Env. Similarly, the V3 domains se-
1 0 0 0
quenced from macaques 8B and 8D had only the argi- 2 1000 1000
nine-to-isoleucine substitution. In no case was a V3 do- 3 100 10 100
4 10 10 10main with the consensus sequence of SHIVKU-1 found in
8 0 0 0the lymph node tissues derived from these macaques.
14 0 0 1Examination of the bone marrow cells from 8A used to
19 0 0 0 1288 1771 1194
inoculate macaques PRc and PLc again revealed the 23 0 0 0 2349 2088 848
presence of the arginine-to-isoleucine substitution in two 31 0 0 1 1570 2410 1420
35 0 0 0 1350 2280 1090of five clones examined and no substitutions in the V3
39 0 0 0 1560 2380 960region in the other three clones. These results were in
48 1940 2590 1330agreement with those obtained from macaque 8A follow-
58 0 0 0
ing challenge with SHIVKU-1 . Examination of the lymph 69 0 0 0 2184 2563 1453
node tissue from macaque PLc and PRc following inocu- 83 0 0 0 1660 1981
86 0 0 1 2075 1986 1680lation with SHIVKU-1 revealed the presence of 8A bone
87 0 0 0 2301 2255 1714marrow sequences but no V3 sequences corresponding
89 0 0 0 1456 1506 703to SHIVKU-1 . Examination of the V3 sequences from the 91 0 0 1140 1144
lymph node tissue of a control macaque inoculated with 92 0 727
SHIVKU-1 showed the four consensus amino acid substitu-
Note. Double underline indicates the time of superinfection.tions associated with this virus (data not shown). Thus,
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TABLE 4 TABLE 6
Presence of SIVmac or SHIV Sequences in Macaque Tissues Inoculated Presence of SIVmac or SHIV Sequences in Macaque Tissues
Inoculated with SIVmac 7F-Lu Followed by Superinfection withwith SIVmac LG1 Followed by Superinfection with SHIVKU-1a
SHIVKU-1a
SIVmac SHIV
SIVmac SHIV
Macaque Macaque
Macaque Macaque
Tissue P7A PIt PMq P7A PIt PMq
Tissue 28X 28Y 28Z 28X 28Y 28Z
PBMC / / / 0 0 0
Mesenteric LN / / / 0 0 0 PBMC / / / / / /
Mesenteric LN / / / / / /Spleen / / / 0 0 0
Lung 0 0 0 0 0 0 Spleen / / / / / /
Lung / / / / / /Liver 0 0 0 0 0 0
Kidney 0 0 0 0 0 0 Liver / / / 0 / /
Kidney / / / / 0 /Small intestine / / / 0 0 0
Frontal cortex / 0 0 0 0 0 Small intestine / / / / / 0
Frontal cortex 0 0 / / / 0Parietal cortex 0 0 0 0 0 0
Occipital cortex 0 0 0 0 0 0 Parietal cortex 0 0 0 / / 0
Occipital cortex 0 0 / / / 0Temporal cortex / 0 0 0 0 0
Internal capsule 0 0 0 0 0 0 Temporal cortex 0 0 0 / / 0
Internal capsule 0 0 / / / 0Basal ganglia 0 0 / 0 0 0
Midbrain / 0 0 0 0 0 Basal ganglia / / / / / 0
Midbrain / 0 / / / 0Brain stem / 0 0 0 0 0
Cerebellum / 0 0 0 0 0 Brain stem / 0 0 / / 0
Cerebellum 0 0 ND / / 0Cervical SC 0 0 0 0 0 0
Thoracic SC 0 0 0 0 0 0 Cervical SC / 0 / / 0 0
Thoracic SC 0 0 / / 0 0Lumbar SC 0 0 0 0 0 0
Lumbar SC 0 0 / / 0 0
a The presence of SIVmac or SHIV sequences was determined using
oligonucleotides and nested PCR specific for each env gene. a The presence of SIVmac or SHIV sequences was determined using
oligonucleotides and nested PCR specific for each env gene. ND, not
done.
these eight animals that were on hand in a ‘‘test of con-
cept’’ experiment. The failure to identify SHIVKU-1 DNA
sequences in the visceral, lymphoid, and CNS tissues of The mechanisms of antiviral resistance to superinfec-
the macaques inoculated with SIVmacLG1 and in the tion induced by SIVmacLG-1 and NP-SHIV are not known.lymph node tissue DNA from the five animals inoculated However, it is clear that the antibody response to the
with NP-SHIV suggested strongly that the resistance that envelope of the immunizing virus SIVmac LG1 did not con-they developed against their first pathogen extended to tribute to the resistance of LG-1-infected animals to infec-
virulent SHIVKU-1 , against which they all developed appar- tion with SHIVKU-1 . Antibodies to gp120 of SIVmacLG-1ent sterilizing resistance. did not even bind the HIV gp120 of SHIVKU-1 , much less
neutralize the latter. In contrast, NP-SHIV did induce neu-
TABLE 5 tralizing antibodies to SHIVKU-1 and these antibodies
could have had a role in the vaccinated animals’ develop-SIVmac p27 in Plasma and CD4/ Counts in PBMC from Macaques
Inoculated with SIVmac 7F-Lu and then with SHIVKU-1 ment of resistance to SHIVKU-1 . However, the similarity in
resistance induced by SIVmacLG-1 and NP-SHIV may
p27 in plasma (pg/ml) CD4//ml have been mediated by cellular immune responses to
the Gag protein that is common to all three viruses. GivenWeek 28X 28Y 28Z 28X 28Y 28Z
that gag-specific CD8/ T cells are cytotoxic to HIV-in-
1 11 75 60 1462 672 670 duced cells (Buseyne et al., 1993; Riviere et al., 1995;
2 3958 2119 4595 1892 616 879 Kalams and Walker,1995), it is tempting to speculate that
4 4154 0 3374 1261 945 562 the inhibition of replication of SHIV KU-1 in vivo was medi-6 1032 82 4457 3 643 24
ated by specific antiviral CD8/ T cells that were induced8 72 90 1613 17 211 7
by the immunizing viruses.10 391 327 2191 4 37 2
12 280 344 2191 4 3 420 In contrast to the immunizing infections caused by
14 465 809 1308 0 30 176 SIVmacLG-1 and NP-SHIV, the infections initiated by
16 0 599 1321 19 5 3 SHIVKU-1 and SIVmac 7F-Lu were not controlled by any18 19 217 967 8 3 3
apparent immune response. Both viruses were in fact20 0 2
so virulent that they even failed to induce binding of
Note. Double underline indicates the time of superinfection. antibodies to viral proteins. The reduction in virus con-
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nia and encephalitis but did not lose CD4/ T cells until
after inoculation with SHIVKU-1 . Thus, animals that were
inoculated first with virulent virus were fully susceptible
to superinfection and disease caused by other viruses.
Our results are in agreement with a previous study
by Bogers et al. (1995), who reported that macaques
inoculated with attenuated SIVBK28 were protected
against challenge with nonpathogenic SHIV as evi-
denced by the failure to recover infectious SHIV from
PBMC of the challenged animals. Similarly, other investi-
gators showed that SHIV-infected macaques that con-
trolled their infection were resistant to disease following
inoculation with virulent SIVmac239 (Miller et al., 1997).
However, since animals with low virus burdens and no
detectable virus in PBMC may still have viral DNA in
visceral lymph nodes we performed a more comprehen-
sive search in tissues of our macaques challenged with
SHIVKU-1 . We examined 6 visceral organs and 12 regions
of the CNS in addition to PBMC for the presence of viral
DNA and virus.
Contrary to the foregoing studies, Letvin et al. (1995)
showed that prior infection with nonpathogenic SHIV
failed to protect three of four animals against challenge
with pathogenic SIVmac251. Pathogenic mechanisms of
this virus are different from those of SHIVKU-1 since it
causes severe disease without causing loss of CD4/
T cells until late in infection. In contrast, the earliest
pathogenic effect of SHIVKU-1 is the precipitous loss of
CD4/ T cells. Failure of NP-SHIV to protect against
SIVmac251 may therefore be due to the unique properties
of the virus.
The inability to detect the challenge virus in any of the
tissues of macaques that underwent ‘‘immunizing infec-
tions’’ suggested that sterilizing immunity is an achiev-FIG. 2. Nucleotide sequence of the V3 domain isolated from the
lymph node tissue DNA of macaques 8A, 8B, 8D, PLc, and PRc. Follow- able end result in the immunization against lentivirus
ing superinfection of macaques with SHIVKU-1 , DNA was extracted from infections. Given the relevance of this study to HIV-1
mesenteric lymph node tissue (LN) at necropsy, and the V3 region of infections, the possibility for the development of a vac-
env was amplified, cloned, and sequenced. The amplified sequences
cine against this virus remains viable. The fortuitous find-were compared to the sequence of SHIV-4 (HXB2 env) and the consen-
ings that both NP-SHIV and SIVmac induced protectivesus sequence of SHIVKU-1 V3 domain (Stephens et al., 1997) (shown at
the top). As shown, none of the V3 sequences isolated from these five immunity against pathogenic SHIVKU-1 , a virus with an
macaques matched the V3 sequence of SHIVKU-1 . envelope glycoprotein distantly related to that of SIVmac ,
suggest that protection against the various subtypes of
HIV-1 with a single vaccine may still be possible (assum-
centration in plasma after the acute phase of infection ing that macaques reflect human experiences with these
was probably due to exhaustion of viral target cells. This viruses). Second, the fact that sterilizing immunity could
was evident in the SHIVKU-1-infected animals in which be induced with vaccine against a virulent virus suggests
loss of CD4/ T cells was evident. Having failed to mount that there would be minimal opportunity for recombina-
antiviral defenses, the animals were clearly susceptible tion between the vaccine virus and any challenge virus
not only to infection with heterologous virus but also to since these viruses failed to cause infection.
their full pathogenic potential. Thus, animals infected
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